News / Health

'Serial Killer' Cells Demolish Leukemia Tumors

Test patients show complete remission or significant improvement

This microscopy image provided by Dr. Carl June on Wednesday, Aug. 10, 2011 shows immune system T-cells, center, binding to beads which cause the cells to divide. The beads, depicted in yellow, are later removed, leaving pure T-cells which are then ready
This microscopy image provided by Dr. Carl June on Wednesday, Aug. 10, 2011 shows immune system T-cells, center, binding to beads which cause the cells to divide. The beads, depicted in yellow, are later removed, leaving pure T-cells which are then ready


Jessica Berman

U.S. researchers say they've been able to modify a patient's immune system T cells, turning them into “serial killer” cells which zero in on cancer and obliterate it.

It’s being called a breakthrough in the treatment of a form of leukemia, a hard to treat and usually fatal blood cancer.  

Chronic lymphocytic leukemia (CLL) is marked by a slow increase in immune system white blood cells, called B lymphocytes. These B cells, as they're known, are manufactured by the bone marrow, the spongy tissue inside bones that also manufactures red blood cells.

Eventually, the healthy blood cells are crowded out by the proliferating B cells, the patient experiences bone marrow failure, and - without a bone marrow transplant - dies.

A transplant of healthy bone marrow from a donor has been the only treatment and potential cure for chronic lymphocytic leukemia. But it is very difficult to find a match and many people with CLL die while waiting. Even with a transplant, experts say only about half of CLL patients survive the procedure.

Three CLL patients who had run out of treatment options were selected for an experiment at the University of Pennsylvania. Researchers genetically engineered another one of their immune system cells, the T lymphocytes, to attack cancerous B cells.

Carl June, a professor of pathology and laboratory medicine at the school’s Abramson Cancer Center, was the study’s lead author.  

“The actual trial exceeded our wildest outcome and imagination actually," says Carl June, professor of pathology and laboratory medicine, who was the study’s lead author, "because what we found is all three patients have had a remarkable anti-tumor response and that literally pounds of leukemia have been eradicated in all three patients.”

Two of the three CLL patients had a complete remission of their disease and there was a significant improvement in the third.

Watch related video story by Vidushi Sinha

The T cells were genetically modified using a harmless virus, which carried an anti-body called a chimeric antigen receptor (CAR). Antibodies are immune system proteins which are produced in response to an infection.  

The CAR was engineered to bind to another protein called CD19 that’s present on the surface of normal B lymphocytes and all CLL tumor cells.  

Scientists say the modified T cells, injected into the patients following standard chemotherapy, homed in on the cancerous B cells inside the bone marrow, each T lymphocyte killing thousands of tumor cells.  

Researcher Michael Kalos says the team also engineered a signaling molecule that binds to CD19, triggering the continued production of thousands of T cells. The genetically engineered cells act as sentries against cancerous B cells should they return.

“We saw a substantial number of cells remaining circulating and in the marrow of patients very, very late after infusion, nine to 12 months, entirely unprecedented in the field," says Kalos. "And finally we saw that those cells, not only did they remain there, but they were able to be triggered, recognize and kill cancer cells when they encountered them again.”

In a report describing the so-called “serial killer” T cell therapy in the New England Journal of Medicine, researchers say it completely obliterated cancer cells in a 64-year-old man with CLL three weeks after treatment, and three to six months later, researchers could detect no sign of disease.

The patient’s marrow began manufacturing healthy B cells to replace the ones that were destroyed as "collateral damage" by the therapy. Cells that did not express CD19 were unaffected.

You May Like

Obama: I Will Do 'Everything I Can' to Close Guantanamo

US president says prison continues 'to inspire jihadists and extremists around the world' More

Sierra Leone Educates on Safe Ebola Burials

Also, country is improving at rapid response to isolated outbreaks, but health workers need to be even faster, officials say More

Christmas Gains Popularity in Vietnam

Increasingly wealthy Vietnamese embrace holiday due to its non-religious glamor, commercial appeal More

This forum has been closed.
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Jane Monheit Christmas Speciali
December 22, 2014 8:15 PM
Chanteuse Jane Monheit sings the holiday classic “Have Yourself a Merry Little Christmas,” and explains why it’s her favorite song of the season.

Video Jane Monheit Christmas Special

Chanteuse Jane Monheit sings the holiday classic “Have Yourself a Merry Little Christmas,” and explains why it’s her favorite song of the season.

Video US Decision on Cuba Underscores Divisions Among Miami Cubans

For decades, older, more conservative Cubans have been gathering at Café Versailles on the corner of Calle Ocho to eat Cuban food and talk politics. After hearing of President Barack Obama’s decision, a number of them gathered in front of the café with posters to protest. VOA's Sharon Behn reports on the situation.

Video Three Cities Bid for Future Obama Presidential Library

President Barack Obama still has two years left in his term in office, but the effort to establish his post-presidential library is already underway. The bid for the Obama Presidential Library is down to four locations in three states -- New York, Hawaii, and Illinois. As VOA’s Kane Farabaugh reports, each of them played an important part in the president’s life before he reached the White House.

Video Cuba Deal is Major Victory for Pope’s Diplomatic Initiatives

Pope Francis played a key role in brokering the US-Cuba deal that was made public earlier this week. It is the most stunning success so far in a series of peacemaking efforts by the pontiff. VOA religion reporter Jerome Socolovsky has more.

Video Fears of More Political Gridlock in 2015

2014 proved to be a difficult year politically for President Barack Obama and a very good year for the U.S. Republican Party. Republican gains in the November midterm elections gave them control of the Senate and House of Representatives for the next two years -- setting the stage for more confrontation and gridlock in the final two years of the Obama presidency. VOA National Correspondent Jim Malone has a preview from Washington.

Video Sudan School Becomes Target of Aerial Attacks

The school dropout rate is at an all-time high in Sudan's South Kordofan state because many schools have been destroyed during the three-year civil war between the government and SPLA-N rebel forces. Adam Bailes visited Sudan's Nuba Mountains' region and reports many children are simply too scared to go to school

Video VOA Reporter Tours Devastated Peshawar School

Islamist militants wearing military uniforms and strapped with explosives attacked a military run school Tuesday in the northwestern Pakistani city of Peshawar. At least 141 people were killed in the horrific attack, most of them young students. VOA reporter Ayaz Gul visited the devastated school and attended the funeral of the principal who courageously tried to save her students from the deadly attack.

Video Nigerians Fleeing Boko Haram Languish in Camp Near Capital

In its five-year effort to impose Islamic law in northeastern Nigeria, the Boko Haram extremist group has killed thousands of people and forced hundreds of thousands to flee. Some of those who ran for their lives now live in squalor on the edges of the capital, Abuja. Chris Stein reports for VOA.

All About America